STAT

Opinion: Alex Azar: Why drug prices keep going up — and why they need to come down

Any system in which so many Americans owe more for a copay than the actual cost of the drug is clearly not set up to serve them, @SecAzar says.
Two years ago this month, President Trump promised the American people that he would stop drug companies from "getting away with murder" with their annual ritual of price increases.

Two years ago this month, President Trump promised the American people that he would stop drug companies from “getting away with murder” with their annual ritual of price increases. Since then, his historic actions on drug pricing have produced historic results. One official measure of drug price inflation was actually negative in 2018, for the first time in almost 50 years.

But many problems remain. This January, drug companies once again announced large price increases — by one analysis averaging around 6 percent per drug. This annual practice of large price hikes must stop, and prices must come down.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Plans For Generic Wegovy, Cough Syrup Warnings, And More
Biocon is developing a generic version of Novo Nordisk's Wegovy and is prepared to conduct a clinical trial next year if needed.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Cigna Biosimilar Plans, A Vertex Deal In South Africa, And More
Cigna plans to make copies of AbbVie's Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.

Related Books & Audiobooks